公开(公告)号：EP3114233B1

公开(公告)日：2018-04-04

申请号：EP15706833.9

申请日：2015-02-27

申请人： Assistance Publique Hôpitaux de Paris ,  Université Paris Diderot (Paris 7) ,  Université De Nice Sophia Antipolis ,  Institut National de la Santé et de la Recherche Médicale (INSERM)

发明人： CHICHE, Johanna ,  THIEBLEMONT, Catherine ,  RICCI, Jean-Ehrland

IPC分类号： C12Q1/68 ,  G01N33/50 ,  G01N33/573 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5052 ,  G01N33/57426 ,  G01N2333/90203 ,  G01N2800/52

摘要： The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.

公开(公告)号：EP2764121A2

公开(公告)日：2014-08-13

申请号：EP12838184.5

申请日：2012-10-05

申请人： Millennium Pharmaceuticals, Inc.

发明人： AMIDON, Benjamin, Stone ,  BROWNELL, James ,  GAVIN, James, M. ,  KOENIG, Erik, M. ,  SINTCHAK, Michael, D. ,  SMITH, Peter, G.

IPC分类号： C12Q1/68 ,  G01N33/567 ,  C12N15/00

CPC分类号： C12Q1/6886 ,  A61K31/519 ,  C07K16/40 ,  C12N9/0008 ,  C12N9/93 ,  C12Q1/25 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y102/02 ,  C12Y603/02 ,  G01N33/5011 ,  G01N33/5023 ,  G01N33/573 ,  G01N33/574 ,  G01N33/57496 ,  G01N2333/9015 ,  G01N2333/90203 ,  G01N2500/04 ,  G01N2800/52

摘要： The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

公开(公告)号：EP2831110B1

公开(公告)日：2018-05-09

申请号：EP13770310.4

申请日：2013-03-14

申请人： The Regents of the University of California ,  Paganini Biopharma, Inc.

发明人： WADEHRA, Madhuri ,  BRAUN, Jonathan ,  GORDON, Lynn, K. ,  LAZAR, Gary, S.

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K16/30 ,  A61K39/00 ,  A61K45/06 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28 ,  G01N33/574

CPC分类号： C07K16/18 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6823 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6869 ,  A61K2039/505 ,  A61K2039/55 ,  C07K16/22 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3069 ,  C07K2317/34 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/4703 ,  G01N2333/70585 ,  G01N2333/70596 ,  G01N2333/90203 ,  A61K2300/00

摘要： Reduction of EMP2 expression and/or anti-EMP2 therapy reduces cancer stem cells in multiple types of cancer. For example, breast cancers stem cells were defined by the presence of HIF-1α, CD44 and ALDH. It is found that anti-EMP2 IgG1 can be used to reduce the numbers of cancer stem cells.

公开(公告)号：EP3279658A1

公开(公告)日：2018-02-07

申请号：EP17184904.5

申请日：2017-08-04

申请人： ARKRAY, Inc.

发明人： Katsuki, Koji ,  Funamoto, Takehiro ,  Murakami, Masaki

IPC分类号： G01N33/52 ,  G01N33/84 ,  C12Q1/26 ,  C12Q1/527

CPC分类号： C12Q1/26 ,  C12Q1/25 ,  C12Q1/28 ,  C12Q1/527 ,  C12Y102/03003 ,  C12Y111/01 ,  C12Y603/01002 ,  G01N21/78 ,  G01N33/52 ,  G01N33/84 ,  G01N2021/752 ,  G01N2021/7773 ,  G01N2021/7783 ,  G01N2333/90203

摘要： A method of quantifying ammonia, the method includes performing a first reaction in which a test liquid containing ammonia is reacted with adenosine triphosphate and L-glutamic acid in the presence of glutamine synthetase to produce phosphoric acid, performing a second reaction in which the produced phosphoric acid is reacted with pyruvic acid in the presence of pyruvate oxidase, and measuring a component consumed or produced by the second reaction, to quantify ammonia, wherein a reaction to produce adenosine triphosphate from adenosine diphosphate mediated by pyruvate kinase is not carried out.

摘要翻译： 一种定量氨的方法，该方法包括进行第一反应，其中含有氨的测试液在谷氨酰胺合成酶存在下与三磷酸腺苷和L-谷氨酸反应以产生磷酸，进行第二反应，其中产生的磷酸 在丙酮酸氧化酶的存在下使丙酮酸与丙酮酸反应，测定第二次反应中消耗或产生的成分，对氨进行定量，其中，不进行由丙酮酸激酶介导的由二磷酸腺苷产生三磷酸腺苷的反应。

公开(公告)号：EP3114233A1

公开(公告)日：2017-01-11

申请号：EP15706833.9

申请日：2015-02-27

申请人： Assistance Publique Hôpitaux de Paris ,  Université Paris Diderot (Paris 7) ,  Université De Nice Sophia Antipolis ,  Institut National de la Santé et de la Recherche Médicale (INSERM)

发明人： CHICHE, Johanna ,  THIEBLEMONT, Catherine ,  RICCI, Jean-Ehrland

IPC分类号： C12Q1/68 ,  G01N33/50 ,  G01N33/573 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5052 ,  G01N33/57426 ,  G01N2333/90203 ,  G01N2800/52

摘要： The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.

摘要翻译： 本发明涉及一种方法，用于在抗CD20抗体与预测患者的响应到处理，所述方法包括测量甘油醛-3-磷酸脱氢酶（GAPDH）的表达在从所述患者获得的B细胞的水平。

公开(公告)号：EP2968542A4

公开(公告)日：2016-08-24

申请号：EP14762902

申请日：2014-03-14

申请人： VARIAN MED SYS INC

发明人： PARRY RENATE

IPC分类号： A61K39/395 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61K31/337 ,  A61K31/7115 ,  A61K33/24 ,  A61K39/3955 ,  A61N5/1064 ,  A61N2005/1098 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N2333/4703 ,  G01N2333/4712 ,  G01N2333/70585 ,  G01N2333/70596 ,  G01N2333/90203 ,  G01N2333/96494 ,  G01N2400/40

摘要： The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-β expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-β inhibitors with ionizing radiation to treat cancer patients.

公开(公告)号：EP3371321A1

公开(公告)日：2018-09-12

申请号：EP16823315.3

申请日：2016-11-04

申请人： Oslo Universitetssykehus HF

发明人： HOVDA, Knut, Erik ,  GADEHOLT, Gaut ,  JACOBSEN, Dag

IPC分类号： C12Q1/26

CPC分类号： G01N31/005 ,  C12Q1/26 ,  C12Q1/28 ,  C12Y111/01007 ,  G01N33/52 ,  G01N33/573 ,  G01N33/725 ,  G01N2333/90203

摘要： The present disclosure relates to compositions and methods for diagnosis, research, and screening for chemicals in biological fluids (e.g., related to methanol poisoning). In particular, the present disclosure relates to point of care systems and methods for detecting formic acid or formate, in biological fluids by means of natural or recombinant formate oxidase.

公开(公告)号：EP2962109A1

公开(公告)日：2016-01-06

申请号：EP14756519.6

申请日：2014-02-26

申请人： Astute Medical, Inc.

发明人： ANDERBERG, Joseph ,  GRAY, Jeff ,  MCPHERSON, Paul ,  NAKAMURA, Kevin ,  KAMPF, James, Patrick

IPC分类号： G01N33/566

CPC分类号： G01N33/6893 ,  G01N2333/4724 ,  G01N2333/565 ,  G01N2333/71 ,  G01N2333/90203 ,  G01N2800/347 ,  G01N2800/60

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine- protein kinase erbB-2, Interferon beta, C-type lectin domain family 11 member A, Glyceraldehyde- 3 -phosphate dehydrogenase, Interferon omega- 1, Coagulation factor VIII, Thrombin- Antithrombin- III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries.

摘要翻译： 本发明涉及用于监测，诊断，预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 具体而言，本发明涉及使用一种或多种配置为检测选自由凝血因子X，凝血因子V，可溶性受体酪氨酸 - 蛋白激酶erbB-2，干扰素β，C型组成的组的肾损伤标志物的测定 凝集素结构域家族11成员A，甘油醛-3-磷酸脱氢酶，干扰素ω-1，凝血因子VIII，凝血酶 - 抗凝血酶-III复合物和可溶性肿瘤坏死因子配体超家族成员13B作为肾损伤中的诊断和预后生物标志物。

公开(公告)号：EP2195027A4

公开(公告)日：2011-11-16

申请号：EP08836174

申请日：2008-10-01

申请人： UNIV JOHNS HOPKINS

发明人： KAPLIN ADAM I ,  KERR DOUGLAS A ,  CALABRESI PETER ARTHUR ,  ALLIE SITHY RAMEEZA

IPC分类号： A61K31/675 ,  A61K38/19 ,  A61K39/395 ,  G01N33/48

CPC分类号： A61K38/193 ,  A61K31/195 ,  A61K31/675 ,  A61K45/06 ,  C12Q1/32 ,  G01N33/5014 ,  G01N33/573 ,  G01N2333/90203 ,  G01N2510/00 ,  G01N2800/28 ,  G01N2800/52 ,  A61K2300/00

公开(公告)号：EP2195027A1

公开(公告)日：2010-06-16

申请号：EP08836174.6

申请日：2008-10-01

申请人： The Johns Hopkins University

发明人： KAPLIN, Adam, I. ,  KERR, Douglas, A. ,  CALABRESI, Peter, Arthur ,  ALLIE, Sithy, Rameeza

IPC分类号： A61K39/395

CPC分类号： A61K38/193 ,  A61K31/195 ,  A61K31/675 ,  A61K45/06 ,  C12Q1/32 ,  G01N33/5014 ,  G01N33/573 ,  G01N2333/90203 ,  G01N2510/00 ,  G01N2800/28 ,  G01N2800/52 ,  A61K2300/00

摘要： Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system.